Katarina LeBlanc

2.6k total citations · 1 hit paper
21 papers, 1.6k citations indexed

About

Katarina LeBlanc is a scholar working on Genetics, Hematology and Oncology. According to data from OpenAlex, Katarina LeBlanc has authored 21 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Genetics, 10 papers in Hematology and 6 papers in Oncology. Recurrent topics in Katarina LeBlanc's work include Mesenchymal stem cell research (7 papers), Hematopoietic Stem Cell Transplantation (7 papers) and Acute Myeloid Leukemia Research (3 papers). Katarina LeBlanc is often cited by papers focused on Mesenchymal stem cell research (7 papers), Hematopoietic Stem Cell Transplantation (7 papers) and Acute Myeloid Leukemia Research (3 papers). Katarina LeBlanc collaborates with scholars based in Sweden, United States and Italy. Katarina LeBlanc's co-authors include Olle Ringdén, Ida Rasmusson, Björn Sundberg, Iván Martín, Jacques Galipeau, Jan A. Nolta, Donald G. Phinney, Mauro Krampera, Sowmya Viswanathan and Yufang Shi and has published in prestigious journals such as American Journal of Obstetrics and Gynecology, Experimental Cell Research and British Journal of Haematology.

In The Last Decade

Katarina LeBlanc

21 papers receiving 1.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Mesenchymal stem versus stromal cells: International Society for Cell & Gene Therapy (ISCT®) Mesenchymal Stromal Cell committee position statement on nomenclature

2019 542 citations Sowmya Viswanathan, Yufang Shi et al. Cytotherapy profile →

Peers

Countries citing papers authored by Katarina LeBlanc

Since Specialization

Citations

This map shows the geographic impact of Katarina LeBlanc's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Katarina LeBlanc with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Katarina LeBlanc more than expected).

Fields of papers citing papers by Katarina LeBlanc

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Katarina LeBlanc. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Katarina LeBlanc. The network helps show where Katarina LeBlanc may publish in the future.

Co-authorship network of co-authors of Katarina LeBlanc

This figure shows the co-authorship network connecting the top 25 collaborators of Katarina LeBlanc. A scholar is included among the top collaborators of Katarina LeBlanc based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Katarina LeBlanc. Katarina LeBlanc is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Mesenchymal stromal cell variables influencing clinical potency: the impact of viability, fitness, route of administration and host predisposition 2021 ·Cytotherapy ·Jacques Galipeau, Mauro Krampera, Katarina LeBlanc, Jan A. Nolta, Donald G. Phinney, Yufang Shi, Karin Tarte, Sowmya Viswanathan, Iván Martín	48
2	The Coronavirus Pandemic: A Pitfall or a Fast Track for Validating Cell Therapy Products? 2020 ·Stem Cells and Development ·Maroun Khoury, Laertis Ikonomou, Massimo Dominici, Katarina LeBlanc, Bruce L. Levine, Daniel J. Weiss	8
3	Treatment of vocal fold scarring with autologous bone marrow-derived human mesenchymal stromal cells—first phase I/II human clinical study 2020 ·Stem Cell Research & Therapy ·Stellan Hertegård, (unknown), (unknown), Katarina LeBlanc	29
4	Cell-based therapies for coronavirus disease 2019: proper clinical investigations are essential 2020 ·Cytotherapy ·Maroun Khoury, Patrícia R. M. Rocco, Donald G. Phinney, Mauro Krampera, Iván Martín, Sowmya Viswanathan, Jan A. Nolta, Katarina LeBlanc, Jacques Galipeau, Daniel J. Weiss	34
5	Mesenchymal stem versus stromal cells: International Society for Cell & Gene Therapy (ISCT®) Mesenchymal Stromal Cell committee position statement on nomenclature breakdown → 2019 ·Cytotherapy ·Sowmya Viswanathan, Yufang Shi, Jacques Galipeau, Mauro Krampera, Katarina LeBlanc, Iván Martín, Jan A. Nolta, Donald G. Phinney, Luc Sensebé	542
6	Progression in patients with low- and intermediate-1-risk del(5q) myelodysplastic syndromes is predicted by a limited subset of mutations 2016 ·Haematologica ·Christian Scharenberg, Valentina Giai, Andrea Pellagatti, Leonie Saft, Marios Dimitriou, Monika Jansson, Martin Jädersten, Alf Grandien, Iyadh Douagi, Donna Neuberg, Katarina LeBlanc, Jacqueline Boultwood, Mohsen Karimi, Sten Eirik W. Jacobsen, Petter Woll, Eva Hellström‐Lindberg	29
7	Immunogenicity of virosomal adjuvanted trivalent influenza vaccination in allogeneic stem cell transplant recipients 2015 ·Transplant Infectious Disease ·Aditya Ambati, Sigrun Einarsdottir, Isabelle Magalhaes, Thomas Poiret, (unknown), Katarina LeBlanc, Mats Brune, Markus Maeurer, Per Ljungman	16
8	Different impact of intermediate and unfavourable cytogenetics at the time of diagnosis on outcome of de novo AML after allo-SCT: a long-term retrospective analysis from a single institution 2012 ·Medical Oncology ·Hareth Nahi, Mats Remberger, Maciej Machaczka, Johanna Ungerstedt, (unknown), Olle Ringdén, Katarina LeBlanc, Per Ljungman, H Hägglund	1
9	Treatment with mesenchymal stromal cells is a risk factor for pneumonia‐related death after allogeneic hematopoietic stem cell transplantation 2012 ·European Journal Of Haematology ·(unknown), Ola Blennow, Katarina LeBlanc, Olle Ringdén, Britt Gustafsson, Jonas Mattsson, Mats Remberger	63
10	Donor cell‐derived acute myeloid leukemia after second allogenic cord blood transplantation in a patient with Fanconi anemia 2011 ·Pediatric Transplantation ·Britt Gustafsson, (unknown), Katarina LeBlanc, Gisela Barbany, Stefan Söderhäll, Jacek Winiarski	11
11	Targeted monitoring of patients at high risk of post‐transplant lymphoproliferative disease by quantitative Epstein–Barr virus polymerase chain reaction 2009 ·Transplant Infectious Disease ·Hamdy Omar, H Hägglund, (unknown), Katarina LeBlanc, Jonas Mattsson, Mats Remberger, Olle Ringdén, E. Sparrelid, Mikael Sundin, Jacek Winiarski, Yun Zhang, Per Ljungman	59
12	Risk factors for acute graft-versus-host disease grades II–IV after reduced intensity conditioning allogeneic stem cell transplantation with unrelated donors—a single centre study 2007 ·Bone Marrow Transplantation ·Mats Remberger, Jonas Mattsson, Zeinab Hassan, Niklas Karlsson, Katarina LeBlanc, (unknown), (unknown), Darius Sairafi, Olle Ringdén	27
13	Human mesenchymal stem cells do not differentiate into cardiomyocytes in a cardiac ischemic xenomodel 2006 ·Annals of Medicine ·Karl‐Henrik Grinnemo, Agneta Månsson‐Broberg, Katarina LeBlanc, Matthias Corbascio, Eva Wärdell, Anwar J. Siddiqui, Xiaojin Hao, Christer Sylvén, Göran Dellgren	58
14	Different outcome of allogeneic transplantation in myelofibrosis using conventional or reduced‐intensity conditioning regimens 2006 ·British Journal of Haematology ·Mats Merup, Vladimir Lazarević, Hareth Nahi, Björn Andréasson, Claes Malm, Lars Nilsson, Mats Brune, Katarina LeBlanc, Jack Kutti, Gunnar Birgegård, (unknown)	41
15	Mesenchymal stem cells inhibit lymphocyte proliferation by mitogens and alloantigens by different mechanisms 2005 ·Experimental Cell Research ·Ida Rasmusson, Olle Ringdén, Björn Sundberg, Katarina LeBlanc	415
16	Graft-versus-host disease is associated with a lower relapse incidence after hematopoietic stem cell transplantation in patients with acute lymphoblastic leukemia 2004 ·Biology of Blood and Marrow Transplantation ·Anna Nordlander, Jonas Mattsson, Olle Ringdén, Katarina LeBlanc, Britt Gustafsson, Per Ljungman, Petter Svenberg, (unknown), Mats Remberger	41
17	Allogenic stem cell transplantation for nonmalignant disorders using matched unrelated donors 2004 ·Biology of Blood and Marrow Transplantation ·Petter Svenberg, Mats Remberger, (unknown), Jonas Mattsson, Katarina LeBlanc, Britt Gustafsson, J Aschan, Lisbeth Barkholt, Jacek Winiarski, Per Ljungman, Olle Ringdén	14
18	G-CSF given after haematopoietic stem cell transplantation using HLA-identical sibling donors is associated to a higher incidence of acute GVHD II–IV 2003 ·Bone Marrow Transplantation ·Mats Remberger, (unknown), J Aschan, Lisbeth Barkholt, Katarina LeBlanc, (unknown), Olle Ringdén	57
19	Donor chimerism across full allogenic barriers achieved by in utero transplantation of fetal mesenchymal stem cells in a case of osteogenesis imperfecta 2003 ·American Journal of Obstetrics and Gynecology ·(unknown), Göran Annerén, Ove Axelssön, (unknown), Katarina LeBlanc, Olle Ringdén	5
20	No evidence for an altered mRNA expression or protein level of haematopoietic cell phosphatase in CD34⁺ bone marrow progenitor cells or mature peripheral blood cells in polycythaemia vera 1997 ·European Journal Of Haematology ·Patrik Andersson, Katarina LeBlanc, (unknown), Jessica Samuelsson	21

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact